2.Progression of Impending Central Retinal Vein Occlusion to the Ischemic Variant Following Intravitreal Bevacizumab.
Korean Journal of Ophthalmology 2010;24(3):179-181
A 60-year-old woman who had experienced two episodes of amaurosis fugax in her right eye presented with vision loss. Two weeks earlier, at a private clinic, she was diagnosed with impending central retinal vein occlusion (CRVO) of the right eye and received an intravitreal injection of bevacizumab. Two weeks after this injection she was diagnosed with ischemic CRVO. At 11-weeks post-presentation, extremely ischemic features were observed with fluorescein angiographic findings of severe vascular attenuation and extensive retinal capillary obliteration. At 22-weeks post-presentation she was diagnosed with neovascular glaucoma; she experienced no visual improvement over the following several months.
Antibodies, Monoclonal/*administration & dosage
;
Disease Progression
;
Female
;
Fluorescein Angiography
;
Glaucoma, Neovascular/complications
;
Humans
;
Injections, Intraocular
;
Ischemia/diagnosis/*etiology/physiopathology
;
Middle Aged
;
Retinal Vein Occlusion/*complications/*drug therapy/physiopathology
;
*Retinal Vessels
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Visual Acuity/drug effects
;
Vitreous Body
3.Comparison of Injection of Intravitreal Drugs with Standard Care in Macular Edema Secondary to Branch Retinal Vein Occlusion.
Kyungmin LEE ; Heeyoung JUNG ; Joonhong SOHN
Korean Journal of Ophthalmology 2014;28(1):19-25
PURPOSE: To compare the long-term efficacy and safety of intravitreal triamcinolon with or without rescue laser therapy (intravitreal triamcinolone injection [IVTA] group), bevacizumab with or without rescue laser treatment (intravitreal bevacizumab injection [IVB] group), or a combination of both with or without rescue laser therapy (IVTA + IVB group), with standard care for patients with macular edema secondary to branch retinal vein occlusion (BRVO). METHODS: We reviewed the medical records of 151 patients treated with intravitreal injection with or without rescue laser for treatment of macular edema caused by BRVO, and who were followed up at 1, 3, 6, 12, and 24 months. During the observation period, rescue grid laser or repeated intravitreal injection with initial drug was performed if recurrence of macular edema was confirmed. Visual acuity, change in visual acuity, and intraocular pressure were compared in each phase. RESULTS: Totals of 16%, 5.6%, and 0% of participants in the three groups showed significant visual loss of more than three lines of the Snellen chart at last follow-up. The IVTA group was the least effective treatment modality, with statistical significance. The development rates of elevated intraocular pressure were similar among the groups. CONCLUSIONS: Although IVTA yielded effects similar to those of standard grid photocoagulation based on the Standard Care vs Corticosteroid for Retinal Vein Occlusion study, IVB or IVTA + IVB with or without rescue laser treatment resulted in improvement in visual acuity at 24 months after the start of treatment and was associated with few serious adverse side effects. Thus, these approaches could be useful for treating macular edema arising secondary to BRVO.
Angiogenesis Inhibitors/administration & dosage
;
Antibodies, Monoclonal, Humanized/*administration & dosage
;
Female
;
Follow-Up Studies
;
Glucocorticoids/administration & dosage
;
Humans
;
Intravitreal Injections
;
Laser Therapy/*methods
;
Macular Edema/diagnosis/etiology/*therapy
;
Male
;
Middle Aged
;
Recurrence
;
Retinal Vein Occlusion/*complications/diagnosis/therapy
;
Retrospective Studies
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Triamcinolone Acetonide/*administration & dosage
;
Vascular Endothelial Growth Factor A/*antagonists & inhibitors
;
Visual Acuity
4.Comparison of Injection of Intravitreal Drugs with Standard Care in Macular Edema Secondary to Branch Retinal Vein Occlusion.
Kyungmin LEE ; Heeyoung JUNG ; Joonhong SOHN
Korean Journal of Ophthalmology 2014;28(1):19-25
PURPOSE: To compare the long-term efficacy and safety of intravitreal triamcinolon with or without rescue laser therapy (intravitreal triamcinolone injection [IVTA] group), bevacizumab with or without rescue laser treatment (intravitreal bevacizumab injection [IVB] group), or a combination of both with or without rescue laser therapy (IVTA + IVB group), with standard care for patients with macular edema secondary to branch retinal vein occlusion (BRVO). METHODS: We reviewed the medical records of 151 patients treated with intravitreal injection with or without rescue laser for treatment of macular edema caused by BRVO, and who were followed up at 1, 3, 6, 12, and 24 months. During the observation period, rescue grid laser or repeated intravitreal injection with initial drug was performed if recurrence of macular edema was confirmed. Visual acuity, change in visual acuity, and intraocular pressure were compared in each phase. RESULTS: Totals of 16%, 5.6%, and 0% of participants in the three groups showed significant visual loss of more than three lines of the Snellen chart at last follow-up. The IVTA group was the least effective treatment modality, with statistical significance. The development rates of elevated intraocular pressure were similar among the groups. CONCLUSIONS: Although IVTA yielded effects similar to those of standard grid photocoagulation based on the Standard Care vs Corticosteroid for Retinal Vein Occlusion study, IVB or IVTA + IVB with or without rescue laser treatment resulted in improvement in visual acuity at 24 months after the start of treatment and was associated with few serious adverse side effects. Thus, these approaches could be useful for treating macular edema arising secondary to BRVO.
Angiogenesis Inhibitors/administration & dosage
;
Antibodies, Monoclonal, Humanized/*administration & dosage
;
Female
;
Follow-Up Studies
;
Glucocorticoids/administration & dosage
;
Humans
;
Intravitreal Injections
;
Laser Therapy/*methods
;
Macular Edema/diagnosis/etiology/*therapy
;
Male
;
Middle Aged
;
Recurrence
;
Retinal Vein Occlusion/*complications/diagnosis/therapy
;
Retrospective Studies
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Triamcinolone Acetonide/*administration & dosage
;
Vascular Endothelial Growth Factor A/*antagonists & inhibitors
;
Visual Acuity
5.Cytomegalovirus Retinitis After Intravitreous Triamcinolone Injection in a Patient with Central Retinal Vein Occlusion.
Korean Journal of Ophthalmology 2008;22(2):143-144
To report a case of cytomegalovirus (CMV) retinitis after intravitreal injection of triamcinolone acetonide (IVTA). A 77-year-old woman with macular edema due to central retinal vein occlusion (CRVO) developed peripheral retinitis 4 months after IVTA. A diagnostic anterior chamber paracentesis was performed to obtain DNA for a polymerase chain reaction (PCR) test for viral retinitis. The PCR test was positive for CMV DNA. Other tests for infective uveitis and immune competence were negative. Four months after presentation, gancyclovir was intravitreously injected a total of 5 times, and the retinitis resolved completely. CMV retinitis is a rare complication of local immunosuppression with IVTA. It can be managed with timely injection of intravitreal gancyclovir until recovery from local immunosuppression.
Aged
;
Antiviral Agents/therapeutic use
;
Cytomegalovirus/genetics
;
Cytomegalovirus Retinitis/diagnosis/drug therapy/*etiology
;
DNA, Viral/analysis
;
Female
;
Ganciclovir/therapeutic use
;
Humans
;
Immunosuppressive Agents/*adverse effects
;
Injections
;
Macular Edema/drug therapy/etiology
;
Polymerase Chain Reaction
;
Retinal Vein Occlusion/complications/*drug therapy
;
Triamcinolone Acetonide/*adverse effects
;
Vitreous Body
6.Comparison Between Intravitreal Bevacizumab and Triamcinolone for Macular Edema Secondary to Branch Retinal Vein Occlusion.
Korean Journal of Ophthalmology 2009;23(4):259-265
PURPOSE: To compare the effects of intravitreal bevacizumab to those of triamcinolone acetonide injection for the treatment of macular edema secondary to branch retinal vein occlusion. METHODS: This retrospective study included 50 eyes of 50 patients who received a single injection of intravitreal bevacizumab (1.25 mg/0.05 mL, 22 eyes) or triamcinolone acetonide (4 mg/0.1 mL, 28 eyes) as the only treatment for macular edema secondary to branch retinal vein occlusion; all patients had a post-injection follow-up duration of >24 weeks. Best corrected visual acuity (BCVA), intraocular pressure (IOP), and central macular thickness (CMT) by optical coherence tomography were measured for up to 24 weeks after injection. RESULTS: BCVA was improved at 1, 4, 8,12 weeks post-injection in the bevacizumab group, and at 1, 4, 8 weeks post-injection in the triamcinolone group. No significant difference was found between the two groups except at 12 weeks. CMT decreased significantly within each group, and no significant difference between groups was found. In the bevacizumab group, no elevated IOP was observed, whereas IOP was significantly increased at 4, 8, and 12 weeks after triamcinolone injection; IOP was therefore significantly different between the two groups. CONCLUSIONS: Intravitreal bevacizumab is a comparatively simple treatment method that can effectively improve BCVA and reduce CMT without ocular and systemic complications. Consequently, intravitreal bevacizumab injections may be useful as both an alternative and primary treatment for macular edema secondary to branch retinal vein occlusion.
Adult
;
Aged
;
Angiogenesis Inhibitors/*administration & dosage
;
Antibodies, Monoclonal/*administration & dosage
;
Female
;
Follow-Up Studies
;
Glucocorticoids/*administration & dosage
;
Humans
;
Injections
;
Macular Edema/diagnosis/*drug therapy/etiology
;
Male
;
Middle Aged
;
Retinal Vein Occlusion/*complications/diagnosis
;
Retrospective Studies
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Triamcinolone Acetonide/*administration & dosage
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Visual Acuity
;
Vitreous Body